尚荣医疗(002551) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥276,144,984.63, a decrease of 10.75% compared to ¥309,400,196.89 in the same period last year[3] - Net profit attributable to shareholders increased by 97.44% to ¥13,883,489.34 from ¥7,031,710.72 year-on-year[3] - Basic earnings per share doubled to ¥0.02 from ¥0.01, reflecting a 100% increase[3] - Net profit for the current period is ¥18,356,313.59, up 136.5% from ¥7,761,054.60 in the previous period[33] - The company recorded a total profit of ¥22,290,097.70, compared to ¥8,273,742.76 in the previous period, marking a significant increase[33] Cash Flow and Assets - The net cash flow from operating activities improved significantly, reaching ¥54,991,837.20, a 282.82% increase from -¥30,079,313.39 in the previous year[3] - Cash and cash equivalents at the end of the period reached ¥563,864,314.81, an increase from ¥430,492,901.99 in the previous period[35] - The company's cash and cash equivalents increased to CNY 616,750,849.52 from CNY 490,318,652.86, representing a growth of approximately 25.8%[29] - The total assets at the end of the reporting period were ¥3,903,427,764.12, a slight decrease of 0.72% from ¥3,931,719,261.37 at the end of the previous year[3] Liabilities and Equity - The total current liabilities decreased to CNY 785,385,629.60 from CNY 829,793,840.92, a reduction of about 5.3%[31] - The company's total equity increased to CNY 2,765,608,865.10 from CNY 2,747,755,815.63, reflecting a growth of approximately 0.65%[31] - The total liabilities decreased to CNY 1,137,818,899.02 from CNY 1,183,963,445.74, a decline of about 3.9%[31] Investment and Income - The company reported a significant increase in investment income of 2620.27%, amounting to ¥1,567,119.37 due to higher returns from financial products[9] - Investment activities generated a net cash flow of ¥75,627,183.78, an increase from ¥64,062,883.84 in the previous period[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 69,326, with the largest shareholder holding 29.54% of the shares[10] - The company plans to repurchase shares with a total amount not exceeding 85.8 million yuan, with a maximum of 2 million shares to be repurchased[24] - The repurchase price is set at no more than 4.29 yuan per share, representing up to 0.24% of the total share capital[24] Project Updates - The company reported a significant order backlog with major contracts totaling ¥15,000 million for the Henan Province Ningling County People's Hospital project and ¥60,000 million for the Shaanxi Province Chengcheng County Hospital project, both of which are in the completion phase[14] - The company has ongoing projects including the Guangdong Province Heshan City People's Hospital construction with a contract value of ¥37,611.19 million, currently in the final stages of construction[14] Restructuring and Impairment - The company is actively monitoring the restructuring of Xuchang Second People's Hospital, with a final arbitration ruling made on December 31, 2021, regarding outstanding payments owed to the company[18] - The total declared debt for the restructuring of the Xuchang Second People's Hospital is estimated at 3.5 billion yuan, with principal debt around 2.9 billion yuan[22] - The company has recognized a credit impairment loss of 177.22 million yuan based on the recoverable value of its debts to the Xuchang Second People's Hospital[22] Other Financial Metrics - The company recorded a 667.29% increase in income tax expenses, amounting to ¥3,421,095.95, due to a rise in total profit[9] - The company's long-term equity investments remained relatively stable at CNY 95,251,585.15, down slightly from CNY 95,565,836.50[29] - The remaining balance of convertible bonds as of March 31, 2024, was CNY 189,564,900, with a total of 8,809 shares converted during the reporting period[26] Audit Status - The company has not undergone an audit for the first quarter report[37]